Responses
Clinical and epidemiological research
Concise report
Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration
Compose a Response to This Article
Other responses
No responses have been published for this article.